drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular therapy (CAR-T)
drug_description
Off-the-shelf, gene-modified T cells from umbilical cord blood expressing chimeric antigen receptors against BCMA (TNFRSF17) and CD19; administered as a single IV infusion to induce T-cell mediated cytotoxicity against malignant plasma and B-lineage cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off‑the‑shelf, umbilical cord blood–derived T cells engineered to express chimeric antigen receptors against BCMA and CD19. Upon binding either antigen on malignant plasma and B‑lineage cells, the CARs trigger T‑cell activation and perforin/granzyme‑mediated cytotoxicity independent of the native TCR, with dual targeting intended to reduce antigen escape.
drug_name
Allogeneic cord blood-derived dual-targeting BCMA/CD19 CAR-T cells
nct_id_drug_ref
NCT07139509